OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
26305056

Eutilex Co Ltd

PharmaceuticalsVerified

Eutilex's capital structure is characterized by a debt-to-equity ratio of 1.02, indicating a balanced but leveraged position relative to its equity base. The company's liquidity is constrained, with a current ratio of 0.44, suggesting that it holds less in current assets than its current liabilities. Free cash flow is negative at -23,078,155,140 KRW, and operating cash flow is also negative at -14,059,760,650 KRW, reflecting ongoing cash outflows from operations. Profitability metrics are negative, with a return on equity of -1.566 and a return on assets of -0.5807. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating loss of -25,630,896,360 KRW and a net loss of -23,923,569,790 KRW further underscore the company's financial challenges. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification increases the company's exposure to sector-specific risks and regional economic fluctuations. Growth trajectory is negative, with the company reporting a net loss and negative cash flows. Historical revenue of 10,294,911,480 KRW does not provide a clear growth pattern, but the current financial performance suggests a lack of momentum. The outlook for the current and next fiscal years is not provided in the data, but the ongoing losses and negative cash flows indicate a challenging near-term environment. Risk factors include medium liquidity risk, as the company's cash and equivalents of 4,397,347,270 KRW are insufficient to cover its short-term obligations. The risk assessment also flags a negative net cash position after subtracting total debt, which could limit the company's ability to fund operations or invest in growth. Dilution risk is currently low, but the company's capital structure and ongoing losses may necessitate future equity raises, which could dilute existing shareholders. Recent events include the company's continued losses and negative cash flows, as disclosed in its latest financial statements. No specific filings or transcripts are provided in the data, but the financial snapshot indicates ongoing operational and financial challenges.

30-day price · 263050(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyEutilex Co Ltd
Ticker263050.KQ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Eutilex Co., Ltd. is a Korea-based company engaged in the production and sale of immunotherapy products, including anticancer T cell therapies and antibody therapies.

Classification. Eutilex is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Eutilex's capital structure is characterized by a debt-to-equity ratio of 1.02, indicating a balanced but leveraged position relative to its equity base. The company's liquidity is constrained, with a current ratio of 0.44, suggesting that it holds less in current assets than its current liabilities. Free cash flow is negative at -23,078,155,140 KRW, and operating cash flow is also negative at -14,059,760,650 KRW, reflecting ongoing cash outflows from operations. Profitability metrics are negative, with a return on equity of -1.566 and a return on assets of -0.5807. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating loss of -25,630,896,360 KRW and a net loss of -23,923,569,790 KRW further underscore the company's financial challenges. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification increases the company's exposure to sector-specific risks and regional economic fluctuations. Growth trajectory is negative, with the company reporting a net loss and negative cash flows. Historical revenue of 10,294,911,480 KRW does not provide a clear growth pattern, but the current financial performance suggests a lack of momentum. The outlook for the current and next fiscal years is not provided in the data, but the ongoing losses and negative cash flows indicate a challenging near-term environment. Risk factors include medium liquidity risk, as the company's cash and equivalents of 4,397,347,270 KRW are insufficient to cover its short-term obligations. The risk assessment also flags a negative net cash position after subtracting total debt, which could limit the company's ability to fund operations or invest in growth. Dilution risk is currently low, but the company's capital structure and ongoing losses may necessitate future equity raises, which could dilute existing shareholders. Recent events include the company's continued losses and negative cash flows, as disclosed in its latest financial statements. No specific filings or transcripts are provided in the data, but the financial snapshot indicates ongoing operational and financial challenges.
Key takeaways
  • Eutilex is operating at a loss with negative cash flows, indicating significant financial distress.
  • The company's debt-to-equity ratio is balanced but leveraged, and its liquidity position is weak.
  • Profitability metrics are negative, with no clear path to positive returns on equity or assets.
  • The company's business is concentrated in a single segment, increasing exposure to sector-specific risks.
  • Liquidity risk is medium, and the company's net cash position is negative after accounting for total debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$10.29B
Gross profit$404.7M
Operating income-$25.63B
Net income-$23.92B
R&D
SG&A
D&A
SBC
Operating cash flow-$14.06B
CapEx-$648.0M
Free cash flow-$23.08B
Total assets$41.20B
Total liabilities$25.92B
Total equity$15.28B
Cash & equivalents$4.40B
Long-term debt$15.51B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$15.28B
Net cash-$11.11B
Current ratio0.4
Debt/Equity1.0
ROA-58.1%
ROE-1.6%
Cash conversion59.0%
CapEx/Revenue-6.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric263050Activity
Op margin-249.0%-2.9% medp25 -218.9% · p75 9.6%bottom quartile
Net margin-232.4%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin3.9%47.8% medp25 27.6% · p75 68.9%bottom quartile
CapEx / revenue-6.3%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity102.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-03 21:25 UTC#ce0e9ca4
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 21:27 UTCJob: c792622c